FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309553684> ?p ?o ?g. }

• W4309553684 endingPage "114021" @default.
• W4309553684 startingPage "114021" @default.
• W4309553684 abstract "The aggressiveness of melanoma and lack of effective therapies incite the discovery of novel strategies. Recently, a new dual acting hybrid molecule (HM), combining a triazene and a ʟ-tyrosine analogue, was synthesized. HM was designed to specifically be activated by tyrosinase, the enzyme involved in melanin biosynthesis and overexpressed in melanoma. HM displayed remarkable superior antiproliferative activity towards various cancer cell lines compared with temozolomide (TMZ), a triazene drug in clinical use, that acts through DNA alkylation. In B16-F10 cells, HM induced a cell cycle arrest at phase G0/G1 with a 2.8-fold decrease in cell proliferation index. Also, compared to control cells, HM led to a concentration-dependent reduction in tyrosinase activity and increase in caspase 3/7 activity. To maximize the therapeutic performance of HM in vivo, its incorporation in long blood circulating liposomes, containing poly(ethylene glycol) (PEG) at their surface, was performed for passively targeting tumour sites. HM liposomes (LIP HM) exhibited high stability in biological fluids. Preclinical studies demonstrated its safety for systemic administration and in a subcutaneous murine melanoma model, significantly reduced tumour progression. In a metastatic murine melanoma model, a superior antitumour effect was also observed for mice receiving LIP HM, with markedly reduction of lung metastases compared to positive control group (TMZ). Biodistribution studies using 111In-labelled LIP HM demonstrated its ability for passively targeting tumour sites, thus correlating with the high therapeutic effect observed in the two experimental murine melanoma models. Overall, our proposed nanotherapeutic strategy was validated as an effective and safe alternative against melanoma." @default.
• W4309553684 created "2022-11-28" @default.
• W4309553684 creator A5006169277 @default.
• W4309553684 creator A5014997038 @default.
• W4309553684 creator A5023784321 @default.
• W4309553684 creator A5026930755 @default.
• W4309553684 creator A5029435804 @default.
• W4309553684 creator A5041803569 @default.
• W4309553684 creator A5049033644 @default.
• W4309553684 creator A5051521102 @default.
• W4309553684 creator A5054088299 @default.
• W4309553684 creator A5055871767 @default.
• W4309553684 creator A5063192974 @default.
• W4309553684 creator A5071711840 @default.
• W4309553684 creator A5082941446 @default.
• W4309553684 creator A5086710616 @default.
• W4309553684 date "2023-01-01" @default.
• W4309553684 modified "2023-10-17" @default.
• W4309553684 title "Preclinical validation of a new hybrid molecule loaded in liposomes for melanoma management" @default.
• W4309553684 cites W1526790573 @default.
• W4309553684 cites W1932176948 @default.
• W4309553684 cites W1965905617 @default.
• W4309553684 cites W1974946490 @default.
• W4309553684 cites W1984063837 @default.
• W4309553684 cites W2003709444 @default.
• W4309553684 cites W2008116690 @default.
• W4309553684 cites W2010157443 @default.
• W4309553684 cites W2013135703 @default.
• W4309553684 cites W2013470095 @default.
• W4309553684 cites W2022058170 @default.
• W4309553684 cites W2022234371 @default.
• W4309553684 cites W2032903640 @default.
• W4309553684 cites W2037198487 @default.
• W4309553684 cites W2038657188 @default.
• W4309553684 cites W2040701570 @default.
• W4309553684 cites W2049209536 @default.
• W4309553684 cites W2054603277 @default.
• W4309553684 cites W2067210803 @default.
• W4309553684 cites W2076226743 @default.
• W4309553684 cites W2076290485 @default.
• W4309553684 cites W2091982741 @default.
• W4309553684 cites W2097866277 @default.
• W4309553684 cites W2118878458 @default.
• W4309553684 cites W2134642693 @default.
• W4309553684 cites W2143463421 @default.
• W4309553684 cites W2148668302 @default.
• W4309553684 cites W2153153510 @default.
• W4309553684 cites W2163669289 @default.
• W4309553684 cites W2344644350 @default.
• W4309553684 cites W2344850880 @default.
• W4309553684 cites W2465623660 @default.
• W4309553684 cites W2559590044 @default.
• W4309553684 cites W2561199577 @default.
• W4309553684 cites W2591741825 @default.
• W4309553684 cites W2596384400 @default.
• W4309553684 cites W2620719306 @default.
• W4309553684 cites W2766588016 @default.
• W4309553684 cites W2793564579 @default.
• W4309553684 cites W2794339309 @default.
• W4309553684 cites W2893490240 @default.
• W4309553684 cites W2921750385 @default.
• W4309553684 cites W2951120602 @default.
• W4309553684 cites W2955491055 @default.
• W4309553684 cites W2979414078 @default.
• W4309553684 cites W2995145725 @default.
• W4309553684 cites W2998882776 @default.
• W4309553684 cites W3000830807 @default.
• W4309553684 cites W3005220199 @default.
• W4309553684 cites W3007861221 @default.
• W4309553684 cites W3028701894 @default.
• W4309553684 cites W3040859487 @default.
• W4309553684 cites W3088577115 @default.
• W4309553684 cites W3091998280 @default.
• W4309553684 cites W3092249886 @default.
• W4309553684 cites W3094533924 @default.
• W4309553684 cites W3098925421 @default.
• W4309553684 cites W3130154996 @default.
• W4309553684 cites W3198334850 @default.
• W4309553684 doi "https://doi.org/10.1016/j.biopha.2022.114021" @default.
• W4309553684 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36399831" @default.
• W4309553684 hasPublicationYear "2023" @default.
• W4309553684 type Work @default.
• W4309553684 citedByCount "4" @default.
• W4309553684 countsByYear W43095536842023 @default.
• W4309553684 crossrefType "journal-article" @default.
• W4309553684 hasAuthorship W4309553684A5006169277 @default.
• W4309553684 hasAuthorship W4309553684A5014997038 @default.
• W4309553684 hasAuthorship W4309553684A5023784321 @default.
• W4309553684 hasAuthorship W4309553684A5026930755 @default.
• W4309553684 hasAuthorship W4309553684A5029435804 @default.
• W4309553684 hasAuthorship W4309553684A5041803569 @default.
• W4309553684 hasAuthorship W4309553684A5049033644 @default.
• W4309553684 hasAuthorship W4309553684A5051521102 @default.
• W4309553684 hasAuthorship W4309553684A5054088299 @default.
• W4309553684 hasAuthorship W4309553684A5055871767 @default.
• W4309553684 hasAuthorship W4309553684A5063192974 @default.
• W4309553684 hasAuthorship W4309553684A5071711840 @default.
• W4309553684 hasAuthorship W4309553684A5082941446 @default.

• next